Literature DB >> 19877025

De novo malignancies following liver transplantation: impact and recommendations.

J Ignacio Herrero1.   

Abstract

1. De novo malignancy is one of the leading causes of late mortality after liver transplantation. 2. The risks of skin cancers and lymphoma are more than 10-fold greater than the risks in an age-matched and sex-matched general population. 3. Some types of neoplasia, such as lung, head and neck, and colorectal cancer, are more frequent in liver transplant recipients than in an age-matched and sex-matched population. The risks of other frequent malignancies, such as prostate and breast cancer, do not seem to be increased. 4. The most important risks for posttransplant malignancy are Epstein-Barr virus seronegativity (for lymphoma), sun exposure (for skin cancer), smoking, and increasing age. 5. Despite the absence of evidence, general recommendations (such as avoidance of overimmunosuppression, sunlight protection, and cessation of smoking) should be given. Screening protocols may help to detect neoplasia at an early stage of disease. (c) 2009 AASLD.

Entities:  

Mesh:

Year:  2009        PMID: 19877025     DOI: 10.1002/lt.21898

Source DB:  PubMed          Journal:  Liver Transpl        ISSN: 1527-6465            Impact factor:   5.799


  20 in total

Review 1.  [Intensive care treatment before and after liver transplantation].

Authors:  I Graziadei
Journal:  Med Klin Intensivmed Notfmed       Date:  2014-08-22       Impact factor: 0.840

2.  Decision tree analysis to stratify risk of de novo non-melanoma skin cancer following liver transplantation.

Authors:  Tomohiro Tanaka; Michael D Voigt
Journal:  J Cancer Res Clin Oncol       Date:  2018-01-23       Impact factor: 4.553

Review 3.  Therapy for alcoholic liver disease.

Authors:  Maryconi M Jaurigue; Mitchell S Cappell
Journal:  World J Gastroenterol       Date:  2014-03-07       Impact factor: 5.742

4.  Risk Factors and Outcomes of De Novo Cancers (Excluding Nonmelanoma Skin Cancer) After Liver Transplantation for Primary Sclerosing Cholangitis.

Authors:  Mohamad A Mouchli; Siddharth Singh; Edward V Loftus; Lisa Boardman; Jayant Talwalkar; Charles B Rosen; Julie K Heimbach; Russell H Wiesner; Bashar Hasan; John J Poterucha; Watt D Kymberly
Journal:  Transplantation       Date:  2017-08       Impact factor: 4.939

5.  Transplantation vs resection for hepatocellular carcinoma with compensated liver function after downstaging therapy.

Authors:  Jian-Yong Lei; Lu-Nan Yan; Wen-Tao Wang
Journal:  World J Gastroenterol       Date:  2013-07-21       Impact factor: 5.742

6.  mTOR signaling in liver regeneration: Rapamycin combined with growth factor treatment.

Authors:  Suomi Mg Fouraschen; Petra E de Ruiter; Jaap Kwekkeboom; Ron Wf de Bruin; Geert Kazemier; Herold J Metselaar; Hugo W Tilanus; Luc Jw van der Laan; Jeroen de Jonge
Journal:  World J Transplant       Date:  2013-09-24

7.  Coupling AAV-mediated promoterless gene targeting to SaCas9 nuclease to efficiently correct liver metabolic diseases.

Authors:  Alessia De Caneva; Fabiola Porro; Giulia Bortolussi; Riccardo Sola; Michela Lisjak; Adi Barzel; Mauro Giacca; Mark A Kay; Kristian Vlahoviček; Lorena Zentilin; Andrés F Muro
Journal:  JCI Insight       Date:  2019-06-18

8.  Metachronous gastrointestinal stromal tumor and acute leukemia after liver transplantation for cholangiocellular carcinoma: is there a link?

Authors:  Anna Mrzljak; Iva Košuta; Anita Škrtić; Ika Kardum-Skelin; Radovan Vrhovac
Journal:  Case Rep Oncol       Date:  2013-03-23

9.  Early Hepatocellular Carcinoma: Transplantation versus Resection: The Case for Liver Resection.

Authors:  Nishant Merchant; Calvin S David; Steven C Cunningham
Journal:  Int J Hepatol       Date:  2011-04-27

10.  Analysis of adult 20-year survivors after liver transplantation.

Authors:  C Dopazo; I Bilbao; L L Castells; G Sapisochin; C Moreiras; I Campos-Varela; J Echeverri; M Caralt; J L Lázaro; R Charco
Journal:  Hepatol Int       Date:  2014-09-18       Impact factor: 6.047

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.